Gregory Callahan

Gregory Callahan

Auto-generated profile, based on publicly available information

Gregory Callahan

Department of Biomedical Engineering, University of Texas at Austin, 1 University Station, BME 5.202D, C0800, Austin, TX 78712, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2023 in Acta Biomaterialia
Verified
Journal Article
Closed access
ASAndrew D Sligar
Andrew D Sligar
GHGretchen Howe
Gretchen Howe
JGJulia Goldman
Julia Goldman
PFPatricia Felli
Patricia Felli
AGAlmudena Gómez-Hernández
Almudena Gómez-Hernández
Aaron BakerAaron Baker
Aaron Baker

14 April 2023 in Applied Materials Today
Verified
Journal Article
Closed access
GCGregory Callahan
Gregory Callahan
AVAustin Veith
Austin Veith
AMAlberto Madariaga
Alberto Madariaga
MRManuel K. Rausch
Manuel K. Rausch
DSDaniel Stromberg
Daniel Stromberg
ABAaron B. Baker
Aaron B. Baker

1 January 2022 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
ASAndrew D. Sligar
Andrew D. Sligar
GHGretchen Howe
Gretchen Howe
JGJulia Goldman
Julia Goldman
PFPatricia Felli
Patricia Felli
AGAlmudena Gómez-Hernández
Almudena Gómez-Hernández
Aaron BakerAaron Baker
Aaron Baker
Regenerative therapeutics for treating peripheral arterial disease are an appealing strategy for creating more durable solutions for limb ischemia. In this work, we performed preclinical testing of an injectable formulation of syndecan-4 proteoliposomes combined with growth factors as treatment for peripheral ischemia delivered in an alginate hydrogel. We tested this therapy in an advanced model of hindlimb ischemia in rabbits with diabetes and hyperlipidemia. Our studies demonstrate enhancement in vascularity and new blood vessel growth with treatment with syndecan-4 proteoliposomes in combination with FGF-2 or FGF-2/PDGF-BB. The effects of the treatments were particularly effective in enhancing vascularity in the lower limb with a 2-4 increase in blood vessels in the treatment group in comparison to the control group. In addition, we demonstrate that the syndecan-4 proteoliposomes have stability for at least 28 days when stored at 4°C to allow transport and use in the hospital environment. In addition, we performed toxicity studies in the mice and found no toxic effects even when injected at high concentration. Overall, our studies support that syndecan-4 proteoliposomes markedly enhance the therapeutic potential of growth factors in the context of disease and may be promising therapeutics for inducing vascular regeneration in peripheral ischemia. Funding Information: The authors gratefully acknowledge funding through the DOD CDMRP (W81XWH-16-1-0580; W81XWH-16-1-0582) and the National Institutes of Health (1R01HL141761-01) to ABB. Declaration of Interests: The authors have patented the technology presented in this manuscript. Ethics Approval Statement: Studies involving animals were performed with the approval of the University of Texas at Austin and the UTHealth Science Center at Houston Institutional Animal Care and Use Committee (IACUC), the Animal Care and Use Review Office (ACURO) of The United States Army Medical Research and Materiel Command Office of Research Protections, and in accordance with NIH guidelines for animal care.